Neuland Labs Q1FY27 Income ₹650.1 Cr, EBITDA ₹231.1 Cr; CEO Optimistic on Growth
Neuland Laboratories reported Q1FY27 total income of ₹650.1 crore, up 116.3% YoY. EBITDA surged 448.2% to ₹231.1 crore, with margins at 35.5%. PAT rose 975.0% to ₹147.4 crore. CEO Saharsh Davuluri expressed optimism about growth and increasing investments. An earnings call is scheduled for August 5, 2026.
The substantial year-on-year financial improvements and positive outlook from the CEO suggest a significant positive impact on investor sentiment and the company's valuation.
The company reported significant year-on-year growth in total income, EBITDA, PBT, PAT, and EPS. The CEO's commentary is optimistic about future growth and customer engagement.
Neuland Laboratories Limited (NLL) announced its financial results for the quarter ended June 30, 2026. The company reported a total income of ₹650.1 crore, marking a significant year-on-year increase of 116.3% from ₹300.6 crore in Q1FY26. The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) stood at ₹231.1 crore, a substantial rise of 448.2% compared to ₹42.1 crore in the same quarter last year. The EBITDA margin improved to 35.5% from 14.0% year-on-year.
Profit Before Tax (PBT) surged to ₹197.5 crore, a 1036.7% increase from ₹17.4 crore in Q1FY26, with the PBT margin reaching 30.4% compared to 5.8% previously. Consequently, Profit After Tax (PAT) grew by 975.0% to ₹147.4 crore from ₹13.7 crore in Q1FY26. The Earnings Per Share (EPS) also saw a significant jump, rising to ₹114.9 from ₹10.7 year-on-year.
Mr. Saharsh Davuluri, Chief Executive Officer and Managing Director, expressed optimism about the performance, stating that Q1 FY27 was in line with expectations, with encouraging contributions from both CMS & GDS businesses. He highlighted stronger customer conversations and a focus on consistent delivery and building long-term partnerships. Davuluri also indicated that the company's investment intensity is expected to increase based on available opportunities, despite significant Capex investments already underway.
Neuland Laboratories will host an Earnings Call at 17:30 hrs IST on Wednesday, August 5, 2026, to discuss the company's performance. The transcript of the call will be uploaded on the company website in due course.
What to do with a filing like this
Neuland Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neuland Laboratories Limited. Read the original for the full detail.